Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UNR844-Cl · 1 trial · 1 indication
Change from baseline in binocular DCNVA in subjects aged 45 to 55 years at Month 3 after UNR844-Cl or placebo treatment. Low contrast (10% contrast) DCNVA at 40 cm is measured binocularly using an electronic visual acuity testing system. This assessment was performed with subjects corrected for any distance refractive errors. The system provided distance-corrected low contrast near visual acuity in an Early Treatment Diabetic Retinopathy Study (ETDRS) letter numerical score. High monocular DCNVA ETDRS letter scores represent good vision; Low monocular DCNVA ETDRS letter scores represent poor vision.
| Arm | Type | Description |
|---|---|---|
| UNR844-Cl Ophthalmic Solution | EXPERIMENTAL | 1.5% UNR844-Cl ophthalmic solution for twice-daily dosing |
| Placebo Ophthalmic Solution | PLACEBO_COMPARATOR | placebo ophthalmic solution for twice-daily dosing |
| Name | Type | Description |
|---|---|---|
| UNR844-Cl | DRUG | 1.5% Ophthalmic solution for topical ocular administration |
| Placebo | DRUG | placebo |
Inclusion Criteria: * Written informed consent must be obtained before any assessment is performed * Impaired near vision in each eye and when using both eyes, without any near correction * Need a certain level of near correction Exclusion Criteria: * Impaired distance vision in either eye, with ...
UNR844-Cl is an investigational small molecule eye drop being studied for the treatment of presbyopia, an age-related condition that affects the eye's ability to focus on close objects. It is administered topically as eye drops and is currently in clinical development for this indication.
UNR844-Cl is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational eye drop for presbyopia.
UNR844-Cl is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness for treating presbyopia.
UNR844-Cl has one completed Phase 2 clinical trial registered as NCT03809611. This randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of UNR844-Cl eye drops in 125 subjects with presbyopia in the United States. The trial enrolled adults aged 45 years and older.
UNR844-Cl is the chloride salt form of the compound UNR844. The clinical trial for this drug specifically uses the chloride formulation, referred to as UNR844 Chloride or UNR844-Cl, which is administered as eye drops for the treatment of presbyopia.